Pregled bibliografske jedinice broj: 574317
Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial.
Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial. // Knee Surgery, Sports Traumatology, Arthroscopy, 19 (2011), S1; S36-S46 doi:10.1007/s00167-011-1458-4 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 574317 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial.
Autori
Daraboš, NIkica ; Hašpl, Nikica ; Moser, Carsten ; Daraboš, Anela ; Bartolek, Dubravka ; Groenemeyer, Dietrich
Izvornik
Knee Surgery, Sports Traumatology, Arthroscopy (0942-2056) 19
(2011), S1;
S36-S46
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
ACL reconstruction – Autologous conditioned serum – ACS – Osteoarthritis – Interleukin-1 receptor antagonist (IL-1Ra) – Growth factors
Sažetak
Pro-inflammatory cytokines play a pivotal role in osteoarthritis, as well as in bone tunnel widening after ACL reconstructive surgery. A new treatment option is to administer autologous conditioned serum (ACS) containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF, and TGF-β1, among others) in the liquid blood phase. The purpose of this trial was to establish whether the postoperative outcome could be affected by intraarticular application of ACS. In a prospective, randomized, double-blinded, placebo-controlled trial with two parallel groups, 62 patients were treated. Bone tunnel width was measured by CT scans, while clinical efficacy was assessed by patient-administered outcome instruments (WOMAC, IKDC 2000) up to 1 year following the ACL reconstruction in patients receiving either ACS (Group A) or placebo (Group B). We compared the levels and dynamics of IL-1β concentrations in the synovial liquid and examined the correlation between the levels of IL-1β at three different postoperative points. Bone tunnel enlargement was significantly less (6 months: 8%, 12 months: 13%) in Group A than in Group B (6 months: 31%, 12 months: 38%). Clinical outcomes (WOMAC, IKDC 2000) were consistently better in patients treated with ACS at all data points and for all outcome parameters, and there were statistically significant differences in the WOMAC stiffness subscale after 1 year. The decrease in IL-1β synovial fluid concentration was more pronounced in the ACS group, and values were lower, to a statistically significant degree, in the ACS group at day 10. The intraarticular administration/injection of ACS results in decreased bone tunnel widening after ACL reconstructive surgery. Level of evidence Therapeutic study, Randomized controlled trial (significant differences and narrow confidence intervals), Level I.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za traumatologiju,
Klinički bolnički centar Zagreb,
Medicinski fakultet, Split,
Medicinski fakultet, Osijek
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- ABI/INFORM